RE:Alternate Financing for NASH I had a thought of this as well but didn't know how doable it was. It seems a way to force a valuation and also limit the risk to the company somewhat.
SPCEO1 wrote: Paul mentioned they are pursuing alternate methods to finance the NASH phase III trial. What might that include?
One option would be to spin off TH's NASH assets as a spearate company. If they did that it would be fascinating to see the brokers suddenly ascribing value to NASH as they compete to get the lucrative fees in the listing. It should not be too hard to separate the NASH assets either. Probably two of the best companies to compare TH's NASH asset to would be AKER and IVA. They have market caps of $866 million and $535 million respectively.
TH could list TheraNASH (my suggested name) for a valuation of $500 million with TH keeping 60% of TNSH's stock (my suggested symbol) for itself and with the other $200 million going directly to TNSH to fund the trial.
We are at the top of a huge bubble. Brokers like large fee income. Something like this could probably be pulled off.